Kevin Joseph Fitzgerald

Insider Reports History

Entity
Individual
Location
C/O Ovid Therapeutics Inc., 1460 Broadway, Suite 15044, New York, NY
Signature
/s/ Chris Matteodo, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Kevin Joseph Fitzgerald:

Stock Role Class Num Shares Value Price $ Report Date Ownership
ALNYLAM PHARMACEUTICALS, INC. CSO & EVP, Head of Research Common Stock 12.9K $3.28M $254.48 Nov 27, 2024 Direct
ALNYLAM PHARMACEUTICALS, INC. CSO & EVP, Head of Research Common Stock 537 $137K $254.48 Nov 25, 2024 by Managed Account
Ovid Therapeutics Inc. Director Stock Option (Right to Buy) 90K Dec 12, 2024 Direct
ALNYLAM PHARMACEUTICALS, INC. CSO & EVP, Head of Research Stock Option (right to buy) 0 Aug 12, 2024 Direct

Insider Reports Filed by Kevin Joseph Fitzgerald

Symbol Company Period Transactions Value $ Form Type Date Filed Role
OVID Ovid Therapeutics Inc. Dec 12, 2024 1 $0 4 Dec 16, 2024 Director
ALNY ALNYLAM PHARMACEUTICALS, INC. Nov 25, 2024 10 -$755K 4 Nov 27, 2024 CSO & EVP, Head of Research
ALNY ALNYLAM PHARMACEUTICALS, INC. Aug 12, 2024 10 -$4.12M 4 Aug 14, 2024 CSO & EVP, Head of Research
ALNY ALNYLAM PHARMACEUTICALS, INC. Jun 24, 2024 13 -$277K 4 Jun 26, 2024 CSO & EVP, Head of Research
ALNY ALNYLAM PHARMACEUTICALS, INC. Mar 20, 2024 0 $0 3 Mar 28, 2024 CSO & EVP, Head of Research
OVID Ovid Therapeutics Inc. Feb 22, 2024 1 $0 4 Feb 26, 2024 Director
OVID Ovid Therapeutics Inc. Feb 23, 2023 1 $0 4 Feb 27, 2023 Director
OVID Ovid Therapeutics Inc. Feb 3, 2022 1 $0 4 Feb 4, 2022 Director
OVID Ovid Therapeutics Inc. Oct 6, 2021 1 $0 4 Oct 7, 2021 Director
OVID Ovid Therapeutics Inc. Oct 6, 2021 0 $0 3 Oct 7, 2021 Director